COVID-19 Antivirals: Latest Treatments and Updates
Updated: Oct 22
Written by Elizabeth Chernoby in TheSkyMeds Editorial Standards
Medically reviewed by Jonathan Reed, Medical Content Reviewer Nov 25 2025
COVID-19 antivirals are medicines that help stop the coronavirus from multiplying inside the body, reducing the risk of serious illness in eligible patients. Although many people recover from COVID-19 without antiviral treatment, older adults and people with certain medical conditions may benefit from early medication. Current treatment options include Paxlovid, remdesivir, and molnupiravir, but they differ in effectiveness, administration, and safety. Recent clinical guidelines have also clarified treatment recommendations for children and people at higher risk. Starting treatment within the recommended timeframe is particularly important. This guide explains the latest COVID-19 antiviral treatments, 2026 updates, eligibility, side effects, and important precautions.
How Do COVID-19 Antivirals Work?
COVID-19 is caused by SARS-CoV-2, a virus that enters human cells and uses them to produce more copies of itself.
Antiviral medicines interfere with different stages of this process. By limiting viral multiplication, they can reduce the likelihood of illness progressing to severe disease in people who are at increased risk.
These medicines work differently from antibiotics, which treat bacterial infections.
They also differ from vaccines. Vaccination helps prepare the immune system before infection, while antivirals are used after infection develops.
Why Does Early Treatment Matter?
The virus generally multiplies rapidly during the early stages of infection. Antiviral treatment is therefore most useful when started promptly.
The CDC guidance on outpatient COVID-19 treatment , updated on October 8, 2026, recommends starting suitable treatment within five to seven days of symptom onset, depending on the medicine.
Waiting until symptoms become severe can mean missing the recommended treatment window.
What Are the Main COVID-19 Antivirals Available?
Three principal antiviral options are recommended for eligible higher-risk outpatients: nirmatrelvir-ritonavir, remdesivir, and molnupiravir.
Paxlovid: Nirmatrelvir and Ritonavir
Paxlovid contains two medicines. Nirmatrelvir blocks a viral enzyme needed for replication, while ritonavir helps maintain effective nirmatrelvir levels in the body.
It is generally the preferred oral antiviral for eligible patients with mild to moderate COVID-19 who are at increased risk of severe disease.
Treatment must begin within five days of symptom onset.
However, important interactions with other medicines can make Paxlovid unsuitable for some people.
Remdesivir: Intravenous Antiviral
Remdesivir, marketed as Veklury, interferes with the virus's ability to copy its genetic material.
For eligible outpatients, it is usually administered through intravenous infusion over three consecutive days, beginning within seven days of symptom onset.
It is commonly considered when Paxlovid is unsuitable because of medication interactions or other clinical factors.
Remdesivir may also be used in hospitalised patients under appropriate medical supervision.
Molnupiravir: An Alternative Oral Treatment
Molnupiravir, marketed as Lagevrio, causes errors during viral genetic replication, reducing the production of functioning viruses.
It is generally reserved for higher-risk adults when preferred treatments cannot be used or accessed.
Evidence suggests that its ability to prevent serious outcomes is less certain than that of preferred antiviral options, particularly among vaccinated patients.
Comparison of the main COVID-19 antiviral treatments used for eligible outpatients.
Medicine | Administration | Treatment Window | Important Limitation |
Paxlovid | Oral tablets for 5 days | Within 5 days | Significant medication interactions |
Remdesivir | IV infusion for 3 days | Within 7 days | Requires supervised infusions |
Molnupiravir | Oral capsules for 5 days | Within 5 days | Lower or uncertain benefit; pregnancy concerns |
Treatment eligibility, medicine availability, and regulatory approvals vary by country.
Who Should Consider COVID-19 Antiviral Treatment?
Antivirals are primarily recommended for people with mild to moderate COVID-19 who have an increased risk of hospitalisation or death.
Age is an important risk factor, particularly for adults over 65.
Other circumstances that may increase risk include:
Diabetes or certain cardiovascular conditions
Chronic lung or kidney disease
A weakened immune system
Cancer treatment or organ transplantation
Multiple underlying medical conditions
Being unvaccinated or not up to date with recommended vaccinations
Having a risk factor does not automatically mean every antiviral is appropriate.
Do Healthy Adults Need Antivirals?
Most otherwise healthy adults with mild COVID-19 do not routinely need antiviral medication.
Rest, fluids, and appropriate symptom relief are often sufficient.
However, people with risk factors should seek medical advice promptly, even when symptoms initially appear mild.
What Are the Latest COVID-19 Antiviral Updates in 2026?
Current treatment strategies focus on preventing severe outcomes rather than routinely prescribing antivirals to everyone who tests positive.
Updated Recommendations for Children
The September 2026 IDSA COVID-19 treatment guidelines include updated recommendations for antiviral treatment in infants, children, and adolescents.
They address nirmatrelvir-ritonavir use in eligible adolescents and remdesivir use in younger patients according to their risk of severe disease.
In the United States, Paxlovid is approved for qualifying adults and remains authorised under emergency-use provisions for eligible adolescents aged at least 12 years who weigh at least 40 kg.
Remdesivir has broader paediatric treatment eligibility, subject to applicable prescribing criteria.
Changes to US Emergency Authorisations
The FDA's COVID-19 medicines regulatory update explains that existing COVID-19 drug emergency-use authorisations are scheduled to cease being effective on June 29, 2027.
This does not mean approved medicines such as Paxlovid and remdesivir automatically lose their full FDA approvals.
As of October 2026, molnupiravir remains available under US emergency-use authorisation rather than full FDA approval.
These are US regulatory arrangements; other countries have their own approval and access requirements.
The most important advance in COVID-19 treatment is not simply having more medicines available. It is identifying higher-risk patients early, choosing an appropriate antiviral, and starting treatment before the recommended window closes.
How Do Doctors Choose the Right COVID-19 Antiviral?
Doctors consider symptom duration, illness severity, age, existing health conditions, kidney and liver function, and medications already being taken.
Paxlovid is often considered first because it can be taken orally and has evidence supporting its benefit in higher-risk patients.
However, ritonavir can interact with medicines used for heart disease, cholesterol management, and organ transplantation.
The current Paxlovid prescribing information carries a prominent warning about potentially serious drug interactions.
Kidney problems may require a modified prescription rather than automatically ruling out treatment. Severe liver impairment also requires particular caution.
Important dos and don'ts when considering COVID-19 antiviral medicines.
Do | Don't |
Seek early medical advice if you are high risk | Wait for symptoms to become severe |
Share your complete medication list | Assume Paxlovid is safe with every medicine |
Follow the prescribed treatment plan | Change antiviral doses yourself |
Discuss pregnancy or breastfeeding | Assume every antiviral is suitable |
Ask about approved local treatment options | Buy unverified antiviral medicines online |
What About Pregnant or Immunocompromised Patients?
Pregnancy requires individual treatment assessment, but appropriate COVID-19 treatment should not automatically be withheld solely because someone is pregnant.
Molnupiravir is generally avoided during pregnancy because of potential fetal harm.
Some severely immunocompromised patients may require specialist assessment, additional treatment, or extended antiviral courses.
What Happens After Antiviral Treatment?
Antivirals reduce the risk of serious illness in eligible patients, but they do not guarantee immediate recovery.
Some people experience COVID-19 rebound, when symptoms return or a test becomes positive again after initial improvement.
Rebound can happen with or without antiviral treatment and is usually mild.
Patients should follow current local infection-control guidance to reduce transmission.
Antivirals have not been established as a routine treatment for long COVID. Research continues into whether early treatment influences longer-term complications.
Preventive vaccination remains important alongside timely treatment.
What Side Effects and Warning Signs Should You Know?
Paxlovid may cause an altered taste, diarrhoea, or medication interactions.
Remdesivir can cause infusion-related reactions and changes in liver blood tests, requiring appropriate monitoring.
Molnupiravir raises reproductive safety concerns and is not authorised in the US for patients younger than 18 years.
Seek emergency medical care for severe breathing difficulty, persistent chest pain, new confusion, inability to stay awake, or blue or grey discoloration of the lips or skin.
Do not delay emergency care while attempting to obtain antiviral medication.
Conclusion
COVID-19 antivirals remain important for protecting patients at increased risk of severe infection. Paxlovid is generally a preferred outpatient treatment, while remdesivir provides an effective alternative when oral treatment is unsuitable. Molnupiravir has a more limited role because its benefits are less certain.
Updated 2026 guidance also provides clearer recommendations for eligible younger patients and highlights changing US authorisation arrangements.
If you develop COVID-19 symptoms and have risk factors for severe illness, contact a qualified healthcare professional promptly. Early assessment, appropriate medication review, vaccination, and timely treatment can help reduce the risk of serious complications.
Frequently Asked Questions
1 . What is the most effective antiviral for COVID-19?
Paxlovid is generally a preferred option for eligible higher-risk outpatients because it has demonstrated benefits against severe outcomes. However, remdesivir may be more appropriate when drug interactions or other medical factors prevent Paxlovid use.
2 . How soon should COVID-19 antiviral treatment begin?
Paxlovid and molnupiravir should generally begin within five days of symptom onset, while outpatient remdesivir can begin within seven days. Earlier assessment helps determine whether treatment is appropriate and avoids missing the recommended window.
3 . Can vaccinated people still benefit from COVID-19 antivirals?
Yes. Vaccinated people with significant risk factors may still benefit from antiviral treatment. However, the absolute benefit depends on individual risk, previous immunity, and other factors. A healthcare professional can assess eligibility.
4 . Is molnupiravir as effective as Paxlovid?
Current evidence does not support considering molnupiravir equally effective. It has less certain benefits against severe COVID-19 outcomes. Clinicians generally consider it when Paxlovid and remdesivir cannot be used or accessed.
5 . Can COVID-19 symptoms return after Paxlovid?
Yes. Some people experience COVID-19 rebound after initial improvement. Rebound can also occur without antiviral treatment. Most reported episodes are mild, but worsening symptoms require medical assessment.
6 . Are COVID-19 antivirals available for children?
Certain antivirals can be used in eligible children, depending on age, weight, disease severity, and local authorisation. US guidance includes Paxlovid for qualifying adolescents and remdesivir for selected younger patients. Paediatric treatment requires professional assessment.
Comments